Alzheimer's Disease Trial, Recruiting NCT05801380 Sponsor: University of the Philippines Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05801380
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with mild or moderate dementia, based on specific memory and thinking tests carried out by a licensed specialist
  • People who have been clinically diagnosed by an expert neurologist as having probable Alzheimer's disease, using established medical guidelines
  • People who have never taken certain Alzheimer's medications (acetylcholinesterase inhibitors or memantine), or who have not taken these medications in the past three months — except if they stopped due to a bad reaction to the medication
  • People who are 65 years old (confirm with trial site whether this means exactly 65 or 65 and older)
  • People who live in the National Capital Region
  • People who are able to read and understand written and spoken English and Filipino

Who may not be able to join:

  • People whose dementia is caused by structural or blood vessel-related brain changes, other than a small number (two or fewer) of minor lesions seen on a brain scan
  • People whose dementia has been diagnosed as something other than Alzheimer's disease by an expert neurologist
  • People who have had untreated depression or related mental health conditions in the past 6 months
  • People who have taken antibiotic medications in the three months before providing a stool sample for the trial
  • People who have used steroids, immune-boosting medications, or immune-suppressing medications in the past 2 weeks, or who regularly need these medications for immune-related conditions
  • People who have used certain stomach or bowel medications — including proton-pump inhibitors, H2-receptor antagonists, certain antidepressants, narcotic pain medications, anticholinergic drugs, laxatives, or anti-diarrhoeal medications — in the past 4 weeks
  • People who consume large amounts of commercial probiotic products (108 colony-forming units or organisms per day or more)
  • People who have made a major change to their diet in the past month, such as completely removing or significantly increasing a major food group
  • People who have had major surgery on their digestive tract in the past 5 years (removal of the gallbladder or appendix are exceptions)
  • People who have had a major portion of their bowel surgically removed at any point in their life
  • People who have active, uncontrolled digestive or bowel conditions, such as inflammatory bowel disease, irritable bowel syndrome, ongoing infections of the gut, recurring bowel infections, or chronic constipation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fresthel Monica M Climacosa, MD, PhD, University of the Philippines Manila

Phone: +639434744737

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of the Philippines
Registry
ClinicalTrials.gov
Start date
14 February 2022
Est. completion
14 February 2026

Where this trial is recruiting

🇵🇭 Philippines

Primary endpoints

Change in gene signatures; Change in gut microbiome metabolome signatures; Change in metabolome signatures; Change in levels of cognition using the Montreal Cognitive Assessment-Philippines (MoCA-P); Change in levels of cognition using the Mini-Mental State Examination (MMSE); Change in levels of cognition using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov